CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
January 2014—Enzo Life Sciences has expanded its portfolio of drug discovery platforms with the introduction of the new Leading Light Sclerostin-LRP Screening System. Developed to meet the market need for a simple, sensitive biochemical screening assay for detection of sclerostin inhibitors (antagonists of the Wnt signaling pathway), this kit is a drug discovery tool for detecting small molecule inhibitors that disrupt the interaction between SOST and LRP5.
With this kit, Enzo enables the screening of sclerostin inhibitors in a high-throughput, reproducible manner without the need for cell lines or transfection. This rapid, chemiluminescent-based binding assay allows for initial screening of sclerostin inhibitors in less than 2.5 hours. The assay contains human sclerostin immobilized to a 96-well plate and uses an engineered LRP5-alkaline phosphatase conjugate. LRP5-AP binds immobilized sclerostin, producing signal in the development step. Signal decreases when this interaction is blocked by the presence of a sclerostin inhibitor. This system can be used for drug screening to identify small molecule compounds, antibodies, DNA aptamers, and peptides capable of modulating sclerostin-LRP interaction. With the chemiluminescent readout amenable to both 96- and 384-well plate formats, the kit allows for high-throughput analysis of sclerostin inhibitors.
The assay is supplied with an easy-to-follow protocol, a validated acid green 25 inhibitor, and all the necessary media, reagents, and controls.
Enzo Life Sciences, 800-942-0430